SAM
YMAB

Smartleaf Asset Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Smartleaf Asset Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-31
Closed -$401 – 3024
2024
Q3 		$401 Buy
+31
New +$393 ﹤0.01% 2813

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Smartleaf Asset Management's YMAB Position: Q4 2024 in Review

Smartleaf Asset Management sold out of Y-mAbs Therapeutics (YMAB) in Q4 2024, closing a stake of 31 shares — an estimated $401 sold.

Smartleaf Asset Management first reported a position in YMAB in Q3 2024 and held it in 1 quarter. The position peaked at $401 in Q3 2024. 112 funds tracked by Wall St. Rank hold YMAB as of Q4 2024.

  • Smartleaf Asset Management reported no remaining Y-mAbs Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Smartleaf Asset Management sold 31 Y-mAbs Therapeutics shares in Q4 2024, an estimated $401.
  • Smartleaf Asset Management first reported a position in Y-mAbs Therapeutics in Q3 2024 and held it in 1 quarter.
  • Smartleaf Asset Management's Y-mAbs Therapeutics position peaked at $401 in Q3 2024.
  • 112 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2024.

Based on Smartleaf Asset Management's 13F filing for Q4 2024, filed 5 Feb 2025.